

SenzaGen secures 1.3 MSEK order for GARD®skin Dose-Response from leading global chemical company

Lund, August 12, 2024

SenzaGen has received an important testing assignment from a globally leading actor in the chemical industry. The order is valued at approximately 1.3 million SEK and includes testing using SenzaGen's innovative and non-animal test method for skin sensitization, the unique GARD®skin Dose-Response test. Testing will take place at SenzaGen's GLP-certified laboratory in Lund during the fall of 2024.

The customer, a top chemical industry company with a global presence and headquarters in Europe, has been a loyal SenzaGen customer for several years. This testing project aims to establish safe dose levels and assess the risks of specialty chemicals in their product development processes. This new order further strengthens the position of the GARD® technology among leading global customers:

"We are extremely pleased to receive yet another important order from this loyal chemical industry client. This new order confirms that our organic growth strategy continues to deliver excellent results. We not only attract new clients but also build long-term relationships and expand our business with existing ones, creating a foundation for sustained growth. Additionally, this order focuses on GARD®skin Dose-Response, a product we are actively working to broaden in its applications as we pursue OECD approval," says Peter Nählstedt, CEO and Group President of SenzaGen.

The test method GARD®skin Dose-Response is a unique test method that provides quantitative data replacing the need for animal testing to establish safe dose levels of skin sensitizing substances in products. This provides companies in industries such as cosmetics, pharmaceuticals, and chemicals with crucial data for prioritization and decision-making in the research and development of new products.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44



About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

Attachments

[SenzaGen secures 1.3 MSEK order for GARD®skin Dose-Response from leading global chemical company](#)